AXS Investments LLC Buys New Holdings in Shockwave Medical, Inc. (NASDAQ:SWAV)

AXS Investments LLC bought a new stake in Shockwave Medical, Inc. (NASDAQ:SWAV) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,000 shares of the company’s stock, valued at approximately $571,000.

Several other hedge funds have also bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich lifted its position in Shockwave Medical by 98,146.8% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 3,714,713 shares of the company’s stock worth $1,060,216,000 after acquiring an additional 3,710,932 shares during the last quarter. Vanguard Group Inc. lifted its position in Shockwave Medical by 2.1% during the first quarter. Vanguard Group Inc. now owns 3,311,557 shares of the company’s stock worth $686,685,000 after acquiring an additional 67,789 shares during the last quarter. Invesco Ltd. lifted its position in Shockwave Medical by 16.0% during the first quarter. Invesco Ltd. now owns 1,398,211 shares of the company’s stock worth $289,933,000 after acquiring an additional 192,525 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Shockwave Medical by 37.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,394,767 shares of the company’s stock worth $302,428,000 after acquiring an additional 382,374 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Shockwave Medical by 57.9% during the first quarter. JPMorgan Chase & Co. now owns 1,273,747 shares of the company’s stock worth $276,185,000 after acquiring an additional 467,237 shares during the last quarter. 87.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Leerink Partnrs restated an “outperform” rating on shares of Shockwave Medical in a research report on Monday, October 16th. Wells Fargo & Company cut their price objective on shares of Shockwave Medical from $275.00 to $251.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 8th. SVB Leerink began coverage on shares of Shockwave Medical in a research report on Monday, October 16th. They set an “outperform” rating and a $263.00 price objective for the company. Morgan Stanley dropped their price target on shares of Shockwave Medical from $313.00 to $284.00 and set an “overweight” rating for the company in a research report on Tuesday, November 7th. Finally, TheStreet downgraded shares of Shockwave Medical from a “b-” rating to a “c+” rating in a research report on Thursday, August 10th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Shockwave Medical presently has a consensus rating of “Moderate Buy” and an average price target of $269.78.

Shockwave Medical Stock Performance

Shares of NASDAQ:SWAV opened at $172.13 on Friday. The company’s 50 day simple moving average is $198.77 and its 200 day simple moving average is $241.85. The stock has a market capitalization of $6.35 billion, a price-to-earnings ratio of 26.81, a price-to-earnings-growth ratio of 9.41 and a beta of 1.01. The company has a debt-to-equity ratio of 1.22, a current ratio of 14.43 and a quick ratio of 13.19. Shockwave Medical, Inc. has a 1 year low of $157.00 and a 1 year high of $315.95.

Shockwave Medical (NASDAQ:SWAV) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. The business had revenue of $186.02 million for the quarter, compared to analysts’ expectations of $184.71 million. Shockwave Medical had a net margin of 36.33% and a return on equity of 42.41%. The firm’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same period last year, the firm posted $0.92 earnings per share. As a group, research analysts predict that Shockwave Medical, Inc. will post 3.62 EPS for the current fiscal year.

Insider Activity at Shockwave Medical

In other Shockwave Medical news, CEO Douglas Evan Godshall sold 10,000 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $214.62, for a total transaction of $2,146,200.00. Following the sale, the chief executive officer now owns 141,649 shares of the company’s stock, valued at $30,400,708.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the business’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $210.25, for a total transaction of $841,000.00. Following the sale, the insider now owns 44,316 shares of the company’s stock, valued at $9,317,439. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Douglas Evan Godshall sold 10,000 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $214.62, for a total transaction of $2,146,200.00. Following the sale, the chief executive officer now directly owns 141,649 shares in the company, valued at approximately $30,400,708.38. The disclosure for this sale can be found here. Insiders have sold 56,000 shares of company stock valued at $11,476,060 over the last three months. 3.40% of the stock is owned by insiders.

Shockwave Medical Company Profile

ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.